Manipulated anti-HER2 bispecific protein
A protein with targeted HER2 binding domains and modified Fc polypeptides enhances brain penetration, addressing the challenge of treating HER2-positive brain metastases by crossing the blood-brain barrier.
JP2026086568APending Publication Date: 2026-05-26DENALI THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- DENALI THERAPEUTICS INC
- Filing Date
- 2026-02-05
- Publication Date
- 2026-05-26
AI Technical Summary
Technical Problem
Current anti-HER2 therapies fail to effectively treat brain metastases from HER2-positive breast cancer due to the inability of drugs to cross the blood-brain barrier and access intracranial lesions.
Method used
A protein is designed with specific binding domains that target subdomains II and IV of human HER2, fused with Fc polypeptides and scFv, and optionally modified for transferrin receptor binding and reduced effector function, to enhance brain penetration.
Benefits of technology
The protein effectively targets HER2-positive brain metastases by crossing the blood-brain barrier, providing a therapeutic approach for treating intracranial lesions.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026086568000001_ABST
Abstract
This invention provides therapeutic drugs and methods for treating brain metastases from cancer. [Solution] In one embodiment, a bispecific protein having the ability to specifically bind to both subdomain II and subdomain IV of human HER2 is provided. In another embodiment, a method is provided for treating cancer or brain metastases of cancer using a bispecific protein that specifically binds to subdomains II and IV of human HER2.
Need to check novelty before this filing date? Find Prior Art